Erasca, Inc. ((ERAS)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Erasca, Inc. is conducting a Phase 1 clinical study titled A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors. The study aims to determine the safety and tolerability of ERAS-0015 in patients with advanced or metastatic solid tumors with specific RAS mutations, either as a standalone treatment or in combination with other therapies.
Intervention/Treatment: The study tests ERAS-0015, an oral drug, both as a monotherapy and in combination with other agents such as Keytruda and Vectibix, to evaluate its effectiveness in treating advanced solid tumors.
Study Design: This interventional study employs a non-randomized, sequential intervention model with no masking. Its primary purpose is treatment-focused, aiming to optimize dosing for ERAS-0015 alone and in combination with other drugs.
Study Timeline: The study began on May 14, 2025, with the latest update submitted on September 9, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
Market Implications: The successful development of ERAS-0015 could positively influence Erasca, Inc.’s stock performance, given the high demand for effective cancer treatments. This could also impact investor sentiment positively, especially if the drug shows promising results compared to competitors in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.